Skip to content

Study · Not a test of the peptide alone · 2006

1 result

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C

Cancer research1 Jan 2006Cited by 132 (Europe PMC)

PMID16397250 (opens in a new tab)DOI10.1158/0008-5472.can-05-1107 (opens in a new tab)PepBankPUB-16397250
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Mechanism

    At doses that inhibited proliferation, the IGF-IR inhibitor BMS-554417 prevented nuclear accumulation of cyclin D1 in response to LR3 IGF-I in cells.

    In plain wordsIn cells, the drug BMS-554417 stopped cyclin D1 from building up in the nucleus after LR3 IGF-I. The agent tested was BMS-554417.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseNuclear cyclin D1 accumulation in response to LR3 IGF-I
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    prevented nuclear accumulation of cyclin D1 in response to LR3 IGF-I.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.